Development and validation of a three-long noncoding RNA signature for predicting prognosis of patients with gastric cancer

Table 1 Patient characteristics and univariate analysis

Characteristic	n	Disease-free survival			Overall survival
		Time (mo)	P value	F	Time (mo)	P value	F
Age, median, yr			0.14	2.17		0.20	1.72
≥ 60	107	42.46			49.39
< 60	93	50.48			55.79
Gender			0.15	2.10		0.12	2.42
Male	142	43.86			50.23
Female	58	49.58			54.82
Bormann type			0.00	44.98		0.00	43.62
I	15	69.93			69.93
II	88	45.57			51.73
III	94	29.35			36.99
IV	3	15.33			25.00
Tumor size			0.00	28.46		0.00	27.42
≥ 5 cm	87	31.51			39.48
< 5 cm	113	57.46			62.07
Location			0.09	4.91		0.13	4.11
Upper	44	35.22			43.33
Middle	56	49.33			54.92
Low	100	48.92			54.31
Lauren type			0.62	0.96		0.63	0.93
Intestinal	95	45.22			51.26
Mixed	45	41.08			47.06
Diffuse	60	50.23			56.12
Tumor differentiation			0.16	2.00		0.19	1.71
Moderate and well	66	50.80			56.28
Poor	134	44.57			50.74
Vessel invasion			0.00	16.30		0.00	14.73
Yes	59	31.07			38.83
No	141	52.08			57.54
Perineural invasion			0.00	11.24		0.00	11.52
Yes	51	28.01			37.39
No	149	52.14			57.41
TNM stage			0.00	335.89		0.00	360.28
I	42	66.45			66.50
II	47	64.36			68.85
III	109	18.70			28.50
IV	2	5.00			8.50
AC007991.4			0.05	3.77		0.05	3.95
Overexpression	68	53.02			58.07
Weak expression	132	42.70			49.24
AC079385.3			0.00	14.23		0.00	14.71
Overexpression	95	36.26			43.94
Weak expression	105	55.12			59.92
AL109615.2			0.00	10.48		0.02	9.87
Overexpression	113	39.04			46.05
Weak expression	87	56.27			60.90
Model			0.00	21.76		0.00	21.34
High risk	95	37.66			44.46
Low risk	105	53.91			59.27

TNM: Tumor-node-metastasis.

Table 2 Multivariate analysis of significant prognostic factors for survival in gastric cancer patients

Variable	Disease-free survival			Overall survival
	P value	HR	95%CI	P value	HR	95%CI
Bormann type	0.20	1.26	0.90-1.77	0.13	1.29	0.93-1.91
Tumor size	0.41	0.86	0.59-1.24	0.40	0.85	0.59-1.24
Vessel invasion	0.06	0.70	0.48-1.01	0.16	0.76	0.53-1.11
Perineural invasion	0.24	0.80	0.56-1.16	0.09	0.73	0.50-1.05
TNM stage	0.00	106.50	30.76-368.77	0.00	94.08	30.14-293.65
Model	0.04	2.27	1.46-3.99	0.03	2.64	1.74-4.27

HR: Hazard ratio; CI: Confidence interval; TNM: Tumor-node-metastasis.

Table 3 Three-long noncoding RNA model and clinicopathologic parameters

Characteristic	Model
	High risk (%)	Low risk (%)	P value	χ2
Age, median, yr			0.11	0.74
≥ 60	52 (48.6)	55 (51.4)
< 60	43 (46.2)	50 (53.8)
Gender			0.27	1.23
Male	71 (50.0)	71 (50.0)
Female	24 (41.4)	34 (58.6)
Bormann type			0.00	14.29
I	2 (13.3)	13 (86.7)
II	36 (40.9)	52 (59.1)
III	56 (59.6)	38 (40.4)
IV	1 (33.3)	2 (66.7)
Tumor size			0.06	3.64
≥ 5 cm	48 (55.2)	39 (44.8)
< 5 cm	47 (41.6)	66 (58.4)
Location			0.77	0.52
Upper	23 (52.3)	21 (47.7)
Middle	26 (46.4)	30 (53.6)
Low	46 (46.0)	54 (54.0)
Lauren type			0.82	0.39
Intestinal	45 (47.4)	50 (52.6)
Mixed	23 (51.1)	22 (48.9)
Diffuse	27 (45.0)	33 (55.0)
Tumor differentiation			0.20	1.72
Moderate and well	27 (40.9)	39 (59.1)
Poor	68 (50.7)	66 (49.3)
Vessel invasion			0.54	0.38
Yes	30 (50.8)	29 (49.2)
No	65 (46.1)	76 (53.9)
Perineural invasion			0.06	3.52
Yes	30 (58.8)	21 (41.2)
No	65 (43.6)	84 (56.4)
TNM stage			0.01	10.85
I	13 (31.0)	29 (69.0)
II	18 (38.3)	29 (61.7)
III	63 (57.8)	46 (42.2)
IV	1 (50.0)	1 (50.0)

TNM: Tumor-node-metastasis.